HARBIN, China, May 17, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company successfully showcased its all-natural products at the 65th PHARMACHINA fair ("the fair") recently held in Chengdu, China.
China Botanic's Compound Schisandra Tablets and Tianma Series attracted attention from many consumers, distributors and members of the media community, who visited the Company's booth. Compound Schisandra Tablets are clinically proven to regulate the central nervous system, nourish the kidneys, cure insomnia and palpitations, and are widely used as treatment for neurasthenia. Tianma Series is a botanic drug which dispels coldness and provides relief from headaches caused by shortage of blood supply and blood stasis with very few side-effects.
The attendees at the fair were pleased with the Company's all-natural product offering, demonstrations and displays. Management estimates an approximate revenue contribution of $0.6 million in fiscal year 2011 from the business generated at the fair.
"PHARMCHINA is China's largest pharmaceutical fair with attendees from all over the country, providing an excellent platform for information exchange, medical cooperation, and exhibition of our products," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are pleased with the response we received at the fair this year and the growing number of opportunities the fair provides to promote our brand and products, and to attract domestic and international customers. We believe this is an excellent opportunity to enhance the Company's visibility among consumers and in the media community. We will continue to participate in similar events to build long-term brand recognition and expand our market reach."
ABOUT PHARMCHINAPHARMCHINA is the largest exhibition in China's pharmaceutical industry. With a history of over 30 years, the PHARMCHINA fair covers an area of approximately 70,000 square meters and attracts over 2,800 exhibitors and 120,000 visitors. Twice a year, exhibitors and visitors attend PHARMCHINA for new business opportunities in the rapidly developing China's pharmaceutical market, including chemical-based drugs, TCM, bio-pharmaceuticals, OTC medicine, health care products, cosmetics, and healthcare-related technologies and other services. For more information, please visit http://en.pharmchina.com.cn/.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:China Botanic Pharmaceutical Inc.Ms. Portia Tan, IR Contact Tel: +86-451-8260-2162Email: email@example.com CCG Investor Relations:Mr. Mark Collinson, PartnerPhone: +1-310-954-1343 (Los Angeles)Email: firstname.lastname@example.org Website: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email: email@example.com
|SOURCE China Botanic Pharmaceutical Inc.|
Copyright©2010 PR Newswire.
All rights reserved